迈威生物-U
(688062)
| 流通市值：72.07亿 | | | 总市值：157.70亿 |
| 流通股本：2.04亿 | | | 总股本：4.47亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 127,597,218.83 | 662,515,554.62 | 565,838,248.14 | 101,165,449.14 |
| 营业收入 | 127,597,218.83 | 662,515,554.62 | 565,838,248.14 | 101,165,449.14 |
| 二、营业总成本 | 356,747,236.67 | 1,634,418,367.37 | 1,164,855,191.83 | 671,700,790.36 |
| 营业成本 | 30,432,803.26 | 64,463,671.1 | 38,773,089.89 | 21,547,809.1 |
| 税金及附加 | 1,833,743.99 | 12,100,086.23 | 10,042,665.88 | 4,544,810.47 |
| 销售费用 | 68,909,367.71 | 225,255,980.57 | 153,265,800.26 | 102,204,799.24 |
| 管理费用 | 61,291,320.04 | 268,571,223.41 | 192,243,774.52 | 115,046,428.1 |
| 研发费用 | 164,495,504.99 | 976,960,824.37 | 712,154,824.51 | 392,091,498.1 |
| 财务费用 | 29,784,496.68 | 87,066,581.69 | 58,375,036.77 | 36,265,445.35 |
| 其中:利息费用 | 28,938,739.87 | 90,846,087.76 | 61,678,099.18 | 39,311,526.82 |
| 其中:利息收入 | 2,056,832.13 | 7,609,136.77 | 5,074,031 | 3,426,731.63 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 1,122,391.35 | 280,597.22 | 18,138.89 |
| 加:投资收益 | -3,423,001.22 | -9,601,531.63 | -5,774,855.91 | -2,865,785.93 |
| 资产处置收益 | 299,576.7 | 199,411.91 | - | - |
| 资产减值损失(新) | -1,209,557.54 | -11,264,036.4 | -9,556,144.94 | -7,689,770.12 |
| 信用减值损失(新) | -6,927,816.57 | 2,525,825 | 2,792,834.32 | 3,158,532.46 |
| 其他收益 | 1,529,272.17 | 33,603,036.52 | 28,337,577.24 | 25,471,396.37 |
| 四、营业利润 | -238,881,544.3 | -955,317,716 | -582,936,935.76 | -552,442,829.55 |
| 加:营业外收入 | 810 | 2,193,962.73 | 2,193,880.25 | 2,189,804.79 |
| 减:营业外支出 | 1,270,483.52 | 3,269,954.79 | 1,934,551.08 | 1,922,773.06 |
| 五、利润总额 | -240,151,217.82 | -956,393,708.06 | -582,677,606.59 | -552,175,797.82 |
| 减:所得税费用 | 2,891,629.9 | 15,864,068.18 | 16,919,163.33 | 54,174 |
| 六、净利润 | -243,042,847.72 | -972,257,776.24 | -599,596,769.92 | -552,229,971.82 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -243,042,847.72 | -972,257,776.24 | -599,596,769.92 | -552,229,971.82 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -241,943,587.61 | -969,333,663.43 | -597,660,144.75 | -551,319,064.76 |
| 少数股东损益 | -1,099,260.11 | -2,924,112.81 | -1,936,625.17 | -910,907.06 |
| 扣除非经常损益后的净利润 | -241,806,163.16 | -998,855,292.5 | -622,355,445.23 | -573,539,040.67 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.61 | -2.43 | -1.5 | -1.38 |
| (二)稀释每股收益 | -0.61 | -2.43 | -1.5 | -1.38 |
| 八、其他综合收益 | -759,615.5 | -626,593.53 | 2,664.16 | -42,444.07 |
| 归属于母公司股东的其他综合收益 | -759,615.5 | -626,593.53 | 2,664.16 | -42,444.07 |
| 九、综合收益总额 | -243,802,463.22 | -972,884,369.77 | -599,594,105.76 | -552,272,415.89 |
| 归属于母公司股东的综合收益总额 | -242,703,203.11 | -969,960,256.96 | -597,657,480.59 | -551,361,508.83 |
| 归属于少数股东的综合收益总额 | -1,099,260.11 | -2,924,112.81 | -1,936,625.17 | -910,907.06 |
| 公告日期 | 2026-04-29 | 2026-03-25 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |